{"transactions":[{"id":673715,"issuer":{"id":9529,"kind":"organization","name":"Forte Biosciences, Inc."},"owners":[{"id":19061,"kind":"person","name":"VINCENT RICHARD G","position":1,"cik":"0001269341","reported_name":"VINCENT RICHARD G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2026-08-27T20:32:25.000Z","date":"2026-08-27","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":18353,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of Forte Biosciences, Inc. (the \"Issuer\") Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, each outstanding restricted stock unit (a \"Company RSU\"), whether or not vested, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the Merger Consideration, multiplied by (y) the total number of shares subject to such Company RSU immediately prior to the effective time of the Merger."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, each outstanding restricted stock unit (a \"Company RSU\"), whether or not vested, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the Merger Consideration, multiplied by (y) the total number of shares subject to such Company RSU immediately prior to the effective time of the Merger."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the Merger Agreement, each outstanding restricted stock unit (a \"Company RSU\"), whether or not vested, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the Merger Consideration, multiplied by (y) the total number of shares subject to such Company RSU immediately prior to the effective time of the Merger."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":18353},"source":{"system":"sec-edgar","filing":"0001269341-26-000003","document":"form4-08272026_080820.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1419041/000126934126000003/form4-08272026_080820.xml","form_type":"4"}},{"id":673714,"issuer":{"id":9529,"kind":"organization","name":"Forte Biosciences, Inc."},"owners":[{"id":19061,"kind":"person","name":"VINCENT RICHARD G","position":1,"cik":"0001269341","reported_name":"VINCENT RICHARD G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-08-27T20:32:25.000Z","date":"2026-08-27","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":31000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated July 26, 2026 (the \"Merger Agreement\"), by and among Forte Biosciences, Inc. (\"Company\"), argenx BV (\"Parent\"), and Avena Merger Sub Inc., a wholly owned subsidiary of Parent (\"Purchaser\"), each unexercised and outstanding option to purchase shares of Common Stock (a \"Company Option\"), whether or not vested, and which had a per share exercise price that was less than $77.00 per share (\"Merger Consideration\"), was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Merger Consideration over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to Purchaser merging with and into Company (the \"Merger\"), with Company surviving the Merger as a wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"At the effective time of the Merger, each Company Option that is then outstanding and unexercised, whether or not vested and which has a per share exercise price that is equal to or greater than the Merger Consideration, shall be cancelled with no consideration payable therefor."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated July 26, 2026 (the \"Merger Agreement\"), by and among Forte Biosciences, Inc. (\"Company\"), argenx BV (\"Parent\"), and Avena Merger Sub Inc., a wholly owned subsidiary of Parent (\"Purchaser\"), each unexercised and outstanding option to purchase shares of Common Stock (a \"Company Option\"), whether or not vested, and which had a per share exercise price that was less than $77.00 per share (\"Merger Consideration\"), was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Merger Consideration over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to Purchaser merging with and into Company (the \"Merger\"), with Company surviving the Merger as a wholly owned subsidiary of Parent."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"At the effective time of the Merger, each Company Option that is then outstanding and unexercised, whether or not vested and which has a per share exercise price that is equal to or greater than the Merger Consideration, shall be cancelled with no consideration payable therefor."}],"balance_after":0,"derivative":{"exercise_price":7.54,"expiration_date":"2035-03-20","underlying":"Common Stock","underlying_shares":31000},"source":{"system":"sec-edgar","filing":"0001269341-26-000003","document":"form4-08272026_080820.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1419041/000126934126000003/form4-08272026_080820.xml","form_type":"4"}},{"id":673713,"issuer":{"id":9529,"kind":"organization","name":"Forte Biosciences, Inc."},"owners":[{"id":19061,"kind":"person","name":"VINCENT RICHARD G","position":1,"cik":"0001269341","reported_name":"VINCENT RICHARD G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-08-27T20:32:25.000Z","date":"2026-08-27","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":2000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated July 26, 2026 (the \"Merger Agreement\"), by and among Forte Biosciences, Inc. (\"Company\"), argenx BV (\"Parent\"), and Avena Merger Sub Inc., a wholly owned subsidiary of Parent (\"Purchaser\"), each unexercised and outstanding option to purchase shares of Common Stock (a \"Company Option\"), whether or not vested, and which had a per share exercise price that was less than $77.00 per share (\"Merger Consideration\"), was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Merger Consideration over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to Purchaser merging with and into Company (the \"Merger\"), with Company surviving the Merger as a wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"At the effective time of the Merger, each Company Option that is then outstanding and unexercised, whether or not vested and which has a per share exercise price that is equal to or greater than the Merger Consideration, shall be cancelled with no consideration payable therefor."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated July 26, 2026 (the \"Merger Agreement\"), by and among Forte Biosciences, Inc. (\"Company\"), argenx BV (\"Parent\"), and Avena Merger Sub Inc., a wholly owned subsidiary of Parent (\"Purchaser\"), each unexercised and outstanding option to purchase shares of Common Stock (a \"Company Option\"), whether or not vested, and which had a per share exercise price that was less than $77.00 per share (\"Merger Consideration\"), was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Merger Consideration over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to Purchaser merging with and into Company (the \"Merger\"), with Company surviving the Merger as a wholly owned subsidiary of Parent."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"At the effective time of the Merger, each Company Option that is then outstanding and unexercised, whether or not vested and which has a per share exercise price that is equal to or greater than the Merger Consideration, shall be cancelled with no consideration payable therefor."}],"balance_after":0,"derivative":{"exercise_price":7.07,"expiration_date":"2034-09-17","underlying":"Common Stock","underlying_shares":2000},"source":{"system":"sec-edgar","filing":"0001269341-26-000003","document":"form4-08272026_080820.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1419041/000126934126000003/form4-08272026_080820.xml","form_type":"4"}},{"id":754516,"issuer":{"id":9529,"kind":"organization","name":"Forte Biosciences, Inc."},"owners":[{"id":19061,"kind":"person","name":"VINCENT RICHARD G","position":1,"cik":"0001269341","reported_name":"VINCENT RICHARD G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2026-06-02T20:38:26.000Z","date":"2026-05-29","kind":"grant","planned":false,"acquired":true,"shares":18353,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of Forte Biosciences, Inc. (the \"Issuer\") Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Subject to the Reporting Person's continuing as a Service Provider (as defined in the 2021 Equity Incentive Plan) through such date, one hundred percent (100%) of the RSUs subject to the award will vest on the date of the first annual meeting of the stockholders that occurs after May 29, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Subject to the Reporting Person's continuing as a Service Provider (as defined in the 2021 Equity Incentive Plan) through such date, one hundred percent (100%) of the RSUs subject to the award will vest on the date of the first annual meeting of the stockholders that occurs after May 29, 2026."}],"balance_after":18353,"derivative":{"underlying":"Common Stock","underlying_shares":18353},"source":{"system":"sec-edgar","filing":"0001269341-26-000002","document":"form4-06022026_080621.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1419041/000126934126000002/form4-06022026_080621.xml","form_type":"4"}},{"id":1194557,"issuer":{"id":9529,"kind":"organization","name":"Forte Biosciences, Inc."},"owners":[{"id":19061,"kind":"person","name":"VINCENT RICHARD G","position":1,"cik":"0001269341","reported_name":"VINCENT RICHARD G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-03-21T20:50:05.000Z","date":"2025-03-20","kind":"grant","planned":false,"acquired":true,"shares":31000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2021 Equity Incentive Plan) through each applicable vesting date, the shares subject to the option shall vest in equal monthly installments over a three (3) year period such that the option shall be fully vested on the third (3rd) anniversary of the Date of Grant.  \"Date of Grant\" shall mean March 20, 2025."}],"balance_after":31000,"derivative":{"exercise_price":7.54,"expiration_date":"2035-03-20","underlying":"Common Stock","underlying_shares":31000},"source":{"system":"sec-edgar","filing":"0001415889-25-008784","document":"form4-03212025_080302.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1419041/000141588925008784/form4-03212025_080302.xml","form_type":"4"}},{"id":1402252,"issuer":{"id":9529,"kind":"organization","name":"Forte Biosciences, Inc."},"owners":[{"id":19061,"kind":"person","name":"VINCENT RICHARD G","position":1,"cik":"0001269341","reported_name":"VINCENT RICHARD G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-09-19T22:30:10.000Z","date":"2024-09-17","kind":"grant","planned":false,"acquired":true,"shares":2000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable vesting date, the shares subject to the option shall vest in equal monthly installments over the thirty six (36) months following the Date of Grant, such that the shares subject to the option shall be fully vested on the third (3rd) anniversary of the Date of Grant. \"Date of Grant\" shall mean September 17, 2024."}],"balance_after":2000,"derivative":{"exercise_price":7.07,"expiration_date":"2034-09-17","underlying":"Common Stock","underlying_shares":2000},"source":{"system":"sec-edgar","filing":"0001415889-24-023723","document":"form4-09192024_100907.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1419041/000141588924023723/form4-09192024_100907.xml","form_type":"4"}},{"id":1640788,"issuer":{"id":89585,"kind":"organization","name":"Oncternal Therapeutics, Inc.","symbol":"ONCT"},"owners":[{"id":19061,"kind":"person","name":"VINCENT RICHARD G","position":1,"cik":"0001269341","reported_name":"VINCENT RICHARD G","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option","published_at":"2024-02-15T23:00:10.000Z","date":"2024-02-14","kind":"grant","planned":false,"acquired":true,"shares":14200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to the stock option vest on first anniversary of the date of grant, and the remaining shares subject to the option vest in 36 equal monthly installments, subject to the recipient's continued employment or service with the Issuer on each such date."}],"balance_after":14200,"derivative":{"exercise_price":9.18,"expiration_date":"2034-02-14","underlying":"Common Stock","underlying_shares":14200},"source":{"system":"sec-edgar","filing":"0001209191-24-003408","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1269341/000120919124003408/doc4.xml","form_type":"4"}},{"id":1685356,"issuer":{"id":89585,"kind":"organization","name":"Oncternal Therapeutics, Inc.","symbol":"ONCT"},"owners":[{"id":19061,"kind":"person","name":"VINCENT RICHARD G","position":1,"cik":"0001269341","reported_name":"VINCENT RICHARD G","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-01-05T21:00:24.000Z","date":"2024-01-03","kind":"tax_withholding","planned":false,"acquired":false,"shares":8868,"price":0.4961,"value":4399.4148,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares withheld by the Issuer to satisfy statutory tax withholding requirements on vesting of restricted stock units."}],"balance_after":140922,"source":{"system":"sec-edgar","filing":"0001209191-24-000972","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1269341/000120919124000972/doc4.xml","form_type":"4"}},{"id":1765120,"issuer":{"id":89585,"kind":"organization","name":"Oncternal Therapeutics, Inc.","symbol":"ONCT"},"owners":[{"id":19061,"kind":"person","name":"VINCENT RICHARD G","position":1,"cik":"0001269341","reported_name":"VINCENT RICHARD G","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option","published_at":"2023-10-04T20:59:48.000Z","date":"2023-10-02","kind":"grant","planned":false,"acquired":true,"shares":210000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F8","text":"The exercise price of the option is $0.31 per share, representing the fair market value per share of the common stock on the grant date; provided that the exercise price will be increased to the original exercise price before repricing if, prior to April 2, 2025: (i) recipient's employment or service terminates, other than due to a Qualifying Termination; or (ii) the option is exercised."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On October 2, 2023, the Issuer repriced the option. Except as described further in footnotes 7 and 8, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"25% of the Option Shares vest on February 21, 2024, and the remaining Option Shares vest in 36 equal monthly installments thereafter, subject to the recipient's continued service."}],"balance_after":210000,"derivative":{"exercise_price":0.31,"expiration_date":"2033-02-21","underlying":"Common Stock","underlying_shares":210000},"source":{"system":"sec-edgar","filing":"0001209191-23-052015","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1269341/000120919123052015/doc4.xml","form_type":"4"}},{"id":1765119,"issuer":{"id":89585,"kind":"organization","name":"Oncternal Therapeutics, Inc.","symbol":"ONCT"},"owners":[{"id":19061,"kind":"person","name":"VINCENT RICHARD G","position":1,"cik":"0001269341","reported_name":"VINCENT RICHARD G","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option","published_at":"2023-10-04T20:59:48.000Z","date":"2023-10-02","kind":"grant","planned":false,"acquired":true,"shares":28750,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F8","text":"The exercise price of the option is $0.31 per share, representing the fair market value per share of the common stock on the grant date; provided that the exercise price will be increased to the original exercise price before repricing if, prior to April 2, 2025: (i) recipient's employment or service terminates, other than due to a Qualifying Termination; or (ii) the option is exercised."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On October 2, 2023, the Issuer repriced the option. Except as described further in footnotes 7 and 8, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"50% of the Option Shares vested on July 3, 2023, and 50% of the Option Shares vest on January 3, 2024, subject to the recipient's continued service. All of the Option Shares vest in the event of a Change in Control (as defined in the Issuer's 2019 Incentive Award Plan)."}],"balance_after":28750,"derivative":{"exercise_price":0.31,"expiration_date":"2032-07-28","underlying":"Common Stock","underlying_shares":28750},"source":{"system":"sec-edgar","filing":"0001209191-23-052015","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1269341/000120919123052015/doc4.xml","form_type":"4"}},{"id":1765118,"issuer":{"id":89585,"kind":"organization","name":"Oncternal Therapeutics, Inc.","symbol":"ONCT"},"owners":[{"id":19061,"kind":"person","name":"VINCENT RICHARD G","position":1,"cik":"0001269341","reported_name":"VINCENT RICHARD G","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option","published_at":"2023-10-04T20:59:48.000Z","date":"2023-10-02","kind":"grant","planned":false,"acquired":true,"shares":109597,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F8","text":"The exercise price of the option is $0.31 per share, representing the fair market value per share of the common stock on the grant date; provided that the exercise price will be increased to the original exercise price before repricing if, prior to April 2, 2025: (i) recipient's employment or service terminates, other than due to a Qualifying Termination; or (ii) the option is exercised."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On October 2, 2023, the Issuer repriced the option. Except as described further in footnotes 7 and 8, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"25% of the Option Shares vested on January 20, 2023, and the remaining Option Shares vest in 36 equal monthly installments thereafter, subject to the recipient's continued service."}],"balance_after":109597,"derivative":{"exercise_price":0.31,"expiration_date":"2032-01-20","underlying":"Common Stock","underlying_shares":109597},"source":{"system":"sec-edgar","filing":"0001209191-23-052015","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1269341/000120919123052015/doc4.xml","form_type":"4"}},{"id":1765117,"issuer":{"id":89585,"kind":"organization","name":"Oncternal Therapeutics, Inc.","symbol":"ONCT"},"owners":[{"id":19061,"kind":"person","name":"VINCENT RICHARD G","position":1,"cik":"0001269341","reported_name":"VINCENT RICHARD G","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option","published_at":"2023-10-04T20:59:48.000Z","date":"2023-10-02","kind":"grant","planned":false,"acquired":true,"shares":280000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F7","text":"The exercise price of the option is $0.31 per share, representing the fair market value per share of the common stock on the grant date; provided that the exercise price will be increased to the original exercise price before repricing if, prior to October 2, 2024: (i) recipient's employment or service terminates, other than due to death, disability, or circumstances giving rise to severance under the recipient's employment agreement (a \"Qualifying Termination\"); or (ii) the option is exercised."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On October 2, 2023, the Issuer repriced the option. Except as described further in footnotes 7 and 8, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of the Option Shares vested on February 11, 2022, and the remaining Option Shares vest in 36 equal monthly installments thereafter, subject to the recipient's continued service."}],"balance_after":280000,"derivative":{"exercise_price":0.31,"expiration_date":"2031-02-11","underlying":"Common Stock","underlying_shares":280000},"source":{"system":"sec-edgar","filing":"0001209191-23-052015","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1269341/000120919123052015/doc4.xml","form_type":"4"}},{"id":1765116,"issuer":{"id":89585,"kind":"organization","name":"Oncternal Therapeutics, Inc.","symbol":"ONCT"},"owners":[{"id":19061,"kind":"person","name":"VINCENT RICHARD G","position":1,"cik":"0001269341","reported_name":"VINCENT RICHARD G","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option","published_at":"2023-10-04T20:59:48.000Z","date":"2023-10-02","kind":"grant","planned":false,"acquired":true,"shares":35120,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F7","text":"The exercise price of the option is $0.31 per share, representing the fair market value per share of the common stock on the grant date; provided that the exercise price will be increased to the original exercise price before repricing if, prior to October 2, 2024: (i) recipient's employment or service terminates, other than due to death, disability, or circumstances giving rise to severance under the recipient's employment agreement (a \"Qualifying Termination\"); or (ii) the option is exercised."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On October 2, 2023, the Issuer repriced the option. Except as described further in footnotes 7 and 8, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option (the \"Option Shares\") are fully vested."}],"balance_after":35120,"derivative":{"exercise_price":0.31,"expiration_date":"2030-03-17","underlying":"Common Stock","underlying_shares":35120},"source":{"system":"sec-edgar","filing":"0001209191-23-052015","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1269341/000120919123052015/doc4.xml","form_type":"4"}},{"id":1765115,"issuer":{"id":89585,"kind":"organization","name":"Oncternal Therapeutics, Inc.","symbol":"ONCT"},"owners":[{"id":19061,"kind":"person","name":"VINCENT RICHARD G","position":1,"cik":"0001269341","reported_name":"VINCENT RICHARD G","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option","published_at":"2023-10-04T20:59:48.000Z","date":"2023-10-02","kind":"grant","planned":false,"acquired":true,"shares":75000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F7","text":"The exercise price of the option is $0.31 per share, representing the fair market value per share of the common stock on the grant date; provided that the exercise price will be increased to the original exercise price before repricing if, prior to October 2, 2024: (i) recipient's employment or service terminates, other than due to death, disability, or circumstances giving rise to severance under the recipient's employment agreement (a \"Qualifying Termination\"); or (ii) the option is exercised."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On October 2, 2023, the Issuer repriced the option. Except as described further in footnotes 7 and 8, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option (the \"Option Shares\") are fully vested."}],"balance_after":75000,"derivative":{"exercise_price":0.31,"expiration_date":"2029-09-12","underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0001209191-23-052015","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1269341/000120919123052015/doc4.xml","form_type":"4"}},{"id":1765114,"issuer":{"id":89585,"kind":"organization","name":"Oncternal Therapeutics, Inc.","symbol":"ONCT"},"owners":[{"id":19061,"kind":"person","name":"VINCENT RICHARD G","position":1,"cik":"0001269341","reported_name":"VINCENT RICHARD G","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option","published_at":"2023-10-04T20:59:48.000Z","date":"2023-10-02","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":210000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On October 2, 2023, the Issuer repriced the option. Except as described further in footnotes 7 and 8, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"25% of the Option Shares vest on February 21, 2024, and the remaining Option Shares vest in 36 equal monthly installments thereafter, subject to the recipient's continued service."}],"balance_after":0,"derivative":{"exercise_price":0.96,"expiration_date":"2033-02-21","underlying":"Common Stock","underlying_shares":210000},"source":{"system":"sec-edgar","filing":"0001209191-23-052015","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1269341/000120919123052015/doc4.xml","form_type":"4"}},{"id":1765113,"issuer":{"id":89585,"kind":"organization","name":"Oncternal Therapeutics, Inc.","symbol":"ONCT"},"owners":[{"id":19061,"kind":"person","name":"VINCENT RICHARD G","position":1,"cik":"0001269341","reported_name":"VINCENT RICHARD G","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option","published_at":"2023-10-04T20:59:48.000Z","date":"2023-10-02","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":28750,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On October 2, 2023, the Issuer repriced the option. Except as described further in footnotes 7 and 8, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"50% of the Option Shares vested on July 3, 2023, and 50% of the Option Shares vest on January 3, 2024, subject to the recipient's continued service. All of the Option Shares vest in the event of a Change in Control (as defined in the Issuer's 2019 Incentive Award Plan)."}],"balance_after":0,"derivative":{"exercise_price":1.04,"expiration_date":"2032-07-28","underlying":"Common Stock","underlying_shares":28750},"source":{"system":"sec-edgar","filing":"0001209191-23-052015","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1269341/000120919123052015/doc4.xml","form_type":"4"}},{"id":1765112,"issuer":{"id":89585,"kind":"organization","name":"Oncternal Therapeutics, Inc.","symbol":"ONCT"},"owners":[{"id":19061,"kind":"person","name":"VINCENT RICHARD G","position":1,"cik":"0001269341","reported_name":"VINCENT RICHARD G","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option","published_at":"2023-10-04T20:59:48.000Z","date":"2023-10-02","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":109579,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On October 2, 2023, the Issuer repriced the option. Except as described further in footnotes 7 and 8, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"25% of the Option Shares vested on January 20, 2023, and the remaining Option Shares vest in 36 equal monthly installments thereafter, subject to the recipient's continued service."}],"balance_after":0,"derivative":{"exercise_price":1.94,"expiration_date":"2032-01-20","underlying":"Common Stock","underlying_shares":109579},"source":{"system":"sec-edgar","filing":"0001209191-23-052015","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1269341/000120919123052015/doc4.xml","form_type":"4"}},{"id":1765111,"issuer":{"id":89585,"kind":"organization","name":"Oncternal Therapeutics, Inc.","symbol":"ONCT"},"owners":[{"id":19061,"kind":"person","name":"VINCENT RICHARD G","position":1,"cik":"0001269341","reported_name":"VINCENT RICHARD G","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option","published_at":"2023-10-04T20:59:48.000Z","date":"2023-10-02","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":280000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On October 2, 2023, the Issuer repriced the option. Except as described further in footnotes 7 and 8, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of the Option Shares vested on February 11, 2022, and the remaining Option Shares vest in 36 equal monthly installments thereafter, subject to the recipient's continued service."}],"balance_after":0,"derivative":{"exercise_price":7.05,"expiration_date":"2031-02-11","underlying":"Common Stock","underlying_shares":280000},"source":{"system":"sec-edgar","filing":"0001209191-23-052015","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1269341/000120919123052015/doc4.xml","form_type":"4"}},{"id":1765110,"issuer":{"id":89585,"kind":"organization","name":"Oncternal Therapeutics, Inc.","symbol":"ONCT"},"owners":[{"id":19061,"kind":"person","name":"VINCENT RICHARD G","position":1,"cik":"0001269341","reported_name":"VINCENT RICHARD G","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option","published_at":"2023-10-04T20:59:48.000Z","date":"2023-10-02","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":35120,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On October 2, 2023, the Issuer repriced the option. Except as described further in footnotes 7 and 8, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option (the \"Option Shares\") are fully vested."}],"balance_after":0,"derivative":{"exercise_price":3.33,"expiration_date":"2030-03-17","underlying":"Common Stock","underlying_shares":35120},"source":{"system":"sec-edgar","filing":"0001209191-23-052015","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1269341/000120919123052015/doc4.xml","form_type":"4"}},{"id":1765109,"issuer":{"id":89585,"kind":"organization","name":"Oncternal Therapeutics, Inc.","symbol":"ONCT"},"owners":[{"id":19061,"kind":"person","name":"VINCENT RICHARD G","position":1,"cik":"0001269341","reported_name":"VINCENT RICHARD G","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option","published_at":"2023-10-04T20:59:48.000Z","date":"2023-10-02","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":75000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On October 2, 2023, the Issuer repriced the option. Except as described further in footnotes 7 and 8, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option (the \"Option Shares\") are fully vested."}],"balance_after":0,"derivative":{"exercise_price":5.76,"expiration_date":"2029-09-12","underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0001209191-23-052015","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1269341/000120919123052015/doc4.xml","form_type":"4"}},{"id":1835607,"issuer":{"id":89585,"kind":"organization","name":"Oncternal Therapeutics, Inc.","symbol":"ONCT"},"owners":[{"id":19061,"kind":"person","name":"VINCENT RICHARD G","position":1,"cik":"0001269341","reported_name":"VINCENT RICHARD G","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-07-05T22:58:35.000Z","date":"2023-07-03","kind":"tax_withholding","planned":false,"acquired":false,"shares":7069,"price":0.36,"value":2544.84,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares withheld by the Issuer to satisfy statutory tax withholding requirements on vesting of restricted stock units."}],"balance_after":149790,"source":{"system":"sec-edgar","filing":"0001209191-23-041316","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1269341/000120919123041316/doc4.xml","form_type":"4"}},{"id":1919469,"issuer":{"id":89585,"kind":"organization","name":"Oncternal Therapeutics, Inc.","symbol":"ONCT"},"owners":[{"id":19061,"kind":"person","name":"VINCENT RICHARD G","position":1,"cik":"0001269341","reported_name":"VINCENT RICHARD G","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-04-14T10:00:10.000Z","date":"2023-04-13","kind":"purchase","planned":false,"acquired":true,"shares":30000,"price":0.2987,"value":8961.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported price is a weighted-average price. These shares were purchased in multiple transactions at prices ranging from $0.2975 to $0.3000. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the SEC Staff, upon request, full information regarding the number of shares purchased at each price within the range set forth above."}],"balance_after":156859,"source":{"system":"sec-edgar","filing":"0001209191-23-024263","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1269341/000120919123024263/doc4.xml","form_type":"4"}},{"id":1995626,"issuer":{"id":89585,"kind":"organization","name":"Oncternal Therapeutics, Inc.","symbol":"ONCT"},"owners":[{"id":19061,"kind":"person","name":"VINCENT RICHARD G","position":1,"cik":"0001269341","reported_name":"VINCENT RICHARD G","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option","published_at":"2023-02-24T01:00:35.000Z","date":"2023-02-21","kind":"grant","acquired":true,"shares":210000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to the stock option vest on first anniversary of the date of grant, and the remaining shares subject to the option vest in 36 equal monthly installments, subject to the recipient's continued employment or service with the Issuer on each such date."}],"balance_after":210000,"derivative":{"exercise_price":0.96,"expiration_date":"2033-02-21","underlying":"Common Stock","underlying_shares":210000},"source":{"system":"sec-edgar","filing":"0001209191-23-012396","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1269341/000120919123012396/doc4.xml","form_type":"4"}},{"id":2062198,"issuer":{"id":89585,"kind":"organization","name":"Oncternal Therapeutics, Inc.","symbol":"ONCT"},"owners":[{"id":19061,"kind":"person","name":"VINCENT RICHARD G","position":1,"cik":"0001269341","reported_name":"VINCENT RICHARD G","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-01-05T23:00:17.000Z","date":"2023-01-03","kind":"tax_withholding","acquired":false,"shares":4428,"price":1.02,"value":4516.56,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares withheld by the Issuer to satisfy statutory tax withholding requirements on vesting of restricted stock units."}],"balance_after":126859,"source":{"system":"sec-edgar","filing":"0001209191-23-002028","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1269341/000120919123002028/doc4.xml","form_type":"4"}},{"id":2198953,"issuer":{"id":89585,"kind":"organization","name":"Oncternal Therapeutics, Inc.","symbol":"ONCT"},"owners":[{"id":19061,"kind":"person","name":"VINCENT RICHARD G","position":1,"cik":"0001269341","reported_name":"VINCENT RICHARD G","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option","published_at":"2022-08-01T22:19:02.000Z","date":"2022-07-28","kind":"grant","acquired":true,"shares":28750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"One half of the shares subject to the stock options vest on July 3, 2023 and one half of the shares subject to the stock options vest on January 3, 2024, subject to the Reporting Person's continued employment or service with the Issuer on each such date. All of the shares subject to the stock options vest in the event of a Change in Control (as defined in the Issuer's 2019 Incentive Award Plan)."}],"balance_after":28750,"derivative":{"exercise_price":1.04,"expiration_date":"2032-07-28","underlying":"Common Stock","underlying_shares":28750},"source":{"system":"sec-edgar","filing":"0001209191-22-043736","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1269341/000120919122043736/doc4.xml","form_type":"4"}},{"id":2198952,"issuer":{"id":89585,"kind":"organization","name":"Oncternal Therapeutics, Inc.","symbol":"ONCT"},"owners":[{"id":19061,"kind":"person","name":"VINCENT RICHARD G","position":1,"cik":"0001269341","reported_name":"VINCENT RICHARD G","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-08-01T22:19:02.000Z","date":"2022-07-28","kind":"grant","acquired":true,"shares":43125,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents an award of restricted stock units (RSUs). Each RSU represents the right to receive one share of the Issuer's common stock upon vesting. One half of the RSUs vest on July 3, 2023, and one half of the RSUs vest on January 3, 2024, subject to the Reporting Person's continued employment or service with the Issuer on each such date. All of the RSUs vest in the event of a Change in Control (as defined in the Issuer's 2019 Incentive Award Plan)."}],"balance_after":131287,"source":{"system":"sec-edgar","filing":"0001209191-22-043736","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1269341/000120919122043736/doc4.xml","form_type":"4"}},{"id":2316478,"issuer":{"id":89585,"kind":"organization","name":"Oncternal Therapeutics, Inc.","symbol":"ONCT"},"owners":[{"id":19061,"kind":"person","name":"VINCENT RICHARD G","position":1,"cik":"0001269341","reported_name":"VINCENT RICHARD G","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-03-28T20:00:38.000Z","date":"2022-03-28","kind":"purchase","acquired":true,"shares":2500,"price":1.4,"value":3500.0,"ownership":{"direct":true},"balance_after":88162,"source":{"system":"sec-edgar","filing":"0001209191-22-021302","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1269341/000120919122021302/doc4.xml","form_type":"4"}},{"id":2316477,"issuer":{"id":89585,"kind":"organization","name":"Oncternal Therapeutics, Inc.","symbol":"ONCT"},"owners":[{"id":19061,"kind":"person","name":"VINCENT RICHARD G","position":1,"cik":"0001269341","reported_name":"VINCENT RICHARD G","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-03-28T20:00:38.000Z","date":"2022-03-25","kind":"purchase","acquired":true,"shares":2136,"price":1.4899,"value":3182.4264,"ownership":{"direct":true},"balance_after":85662,"source":{"system":"sec-edgar","filing":"0001209191-22-021302","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1269341/000120919122021302/doc4.xml","form_type":"4"}},{"id":2316476,"issuer":{"id":89585,"kind":"organization","name":"Oncternal Therapeutics, Inc.","symbol":"ONCT"},"owners":[{"id":19061,"kind":"person","name":"VINCENT RICHARD G","position":1,"cik":"0001269341","reported_name":"VINCENT RICHARD G","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-03-28T20:00:38.000Z","date":"2022-03-25","kind":"purchase","acquired":true,"shares":5,"price":1.48,"value":7.4,"ownership":{"direct":true},"balance_after":83526,"source":{"system":"sec-edgar","filing":"0001209191-22-021302","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1269341/000120919122021302/doc4.xml","form_type":"4"}},{"id":2316475,"issuer":{"id":89585,"kind":"organization","name":"Oncternal Therapeutics, Inc.","symbol":"ONCT"},"owners":[{"id":19061,"kind":"person","name":"VINCENT RICHARD G","position":1,"cik":"0001269341","reported_name":"VINCENT RICHARD G","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-03-28T20:00:38.000Z","date":"2022-03-25","kind":"purchase","acquired":true,"shares":356,"price":1.45,"value":516.2,"ownership":{"direct":true},"balance_after":83521,"source":{"system":"sec-edgar","filing":"0001209191-22-021302","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1269341/000120919122021302/doc4.xml","form_type":"4"}},{"id":2316474,"issuer":{"id":89585,"kind":"organization","name":"Oncternal Therapeutics, Inc.","symbol":"ONCT"},"owners":[{"id":19061,"kind":"person","name":"VINCENT RICHARD G","position":1,"cik":"0001269341","reported_name":"VINCENT RICHARD G","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-03-28T20:00:38.000Z","date":"2022-03-24","kind":"purchase","acquired":true,"shares":3,"price":1.45,"value":4.35,"ownership":{"direct":true},"balance_after":83165,"source":{"system":"sec-edgar","filing":"0001209191-22-021302","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1269341/000120919122021302/doc4.xml","form_type":"4"}},{"id":2420984,"issuer":{"id":89585,"kind":"organization","name":"Oncternal Therapeutics, Inc.","symbol":"ONCT"},"owners":[{"id":19061,"kind":"person","name":"VINCENT RICHARD G","position":1,"cik":"0001269341","reported_name":"VINCENT RICHARD G","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-01-31T21:00:22.000Z","date":"2022-01-28","kind":"purchase","acquired":true,"shares":2500,"price":1.65,"value":4125.0,"ownership":{"direct":true},"balance_after":83162,"source":{"system":"sec-edgar","filing":"0001209191-22-005559","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1269341/000120919122005559/doc4.xml","form_type":"4"}},{"id":2420983,"issuer":{"id":89585,"kind":"organization","name":"Oncternal Therapeutics, Inc.","symbol":"ONCT"},"owners":[{"id":19061,"kind":"person","name":"VINCENT RICHARD G","position":1,"cik":"0001269341","reported_name":"VINCENT RICHARD G","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-01-31T21:00:22.000Z","date":"2022-01-27","kind":"purchase","acquired":true,"shares":5000,"price":1.7,"value":8500.0,"ownership":{"direct":true},"balance_after":80662,"source":{"system":"sec-edgar","filing":"0001209191-22-005559","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1269341/000120919122005559/doc4.xml","form_type":"4"}},{"id":2420982,"issuer":{"id":89585,"kind":"organization","name":"Oncternal Therapeutics, Inc.","symbol":"ONCT"},"owners":[{"id":19061,"kind":"person","name":"VINCENT RICHARD G","position":1,"cik":"0001269341","reported_name":"VINCENT RICHARD G","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-01-31T21:00:22.000Z","date":"2022-01-27","kind":"purchase","acquired":true,"shares":5000,"price":1.8,"value":9000.0,"ownership":{"direct":true},"balance_after":75662,"source":{"system":"sec-edgar","filing":"0001209191-22-005559","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1269341/000120919122005559/doc4.xml","form_type":"4"}},{"id":2427611,"issuer":{"id":89585,"kind":"organization","name":"Oncternal Therapeutics, Inc.","symbol":"ONCT"},"owners":[{"id":19061,"kind":"person","name":"VINCENT RICHARD G","position":1,"cik":"0001269341","reported_name":"VINCENT RICHARD G","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option","published_at":"2022-01-24T21:00:27.000Z","date":"2022-01-20","kind":"grant","acquired":true,"shares":109579,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-fourth of the shares subject to the stock options shall vest on first anniversary of the date of grant, and the remaining shares subject to the option shall vest in 36 equal monthly installments over the three-year period thereafter, subject to the Reporting Person's continued employment or service with the Issuer on each such date."}],"balance_after":109579,"derivative":{"exercise_price":1.94,"expiration_date":"2032-01-20","underlying":"Common Stock","underlying_shares":109579},"source":{"system":"sec-edgar","filing":"0001209191-22-004585","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1269341/000120919122004585/doc4.xml","form_type":"4"}},{"id":2443375,"issuer":{"id":89585,"kind":"organization","name":"Oncternal Therapeutics, Inc.","symbol":"ONCT"},"owners":[{"id":19061,"kind":"person","name":"VINCENT RICHARD G","position":1,"cik":"0001269341","reported_name":"VINCENT RICHARD G","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-01-06T00:00:12.000Z","date":"2022-01-03","kind":"grant","acquired":true,"shares":29867,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents an award of restricted stock units (RSUs). Each RSU represents the right to receive one share of the Issuer's common stock upon vesting. One half of the RSUs vest on January 3, 2023, one quarter of the RSUs vest on July 3, 2023, and one quarter of the RSUs vest on January 3, 2024, subject to the Reporting Person's continued employment or service with the Issuer on each such date. All of the RSUs vest in the event of a Change in Control (as defined in the Issuer's 2019 Incentive Award Plan)."}],"balance_after":70662,"source":{"system":"sec-edgar","filing":"0001209191-22-001971","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1269341/000120919122001971/doc4.xml","form_type":"4"}},{"id":2858691,"issuer":{"id":89585,"kind":"organization","name":"Oncternal Therapeutics, Inc.","symbol":"ONCT"},"owners":[{"id":19061,"kind":"person","name":"VINCENT RICHARD G","position":1,"cik":"0001269341","reported_name":"VINCENT RICHARD G","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option","published_at":"2021-02-16T23:00:44.000Z","date":"2021-02-11","kind":"grant","acquired":true,"shares":280000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-fourth (1/4th) of the shares subject to the stock options shall vest on first anniversary of the date of grant, and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments over the three-year period thereafter, subject to the Reporting Persons continued employment or service with the Issuer on each such date."}],"balance_after":280000,"derivative":{"exercise_price":7.05,"expiration_date":"2031-02-11","underlying":"Common Stock","underlying_shares":280000},"source":{"system":"sec-edgar","filing":"0001209191-21-010903","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1269341/000120919121010903/doc4.xml","form_type":"4"}},{"id":3072399,"issuer":{"id":89585,"kind":"organization","name":"Oncternal Therapeutics, Inc.","symbol":"ONCT"},"owners":[{"id":19061,"kind":"person","name":"VINCENT RICHARD G","position":1,"cik":"0001269341","reported_name":"VINCENT RICHARD G","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2020-08-01T01:05:59.000Z","date":"2020-03-17","kind":"grant","acquired":true,"shares":35120,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The original Form 4 reported the acquisition of the Stock Options in the \"D\" column of Column 5.  This amendment is being filed to correctly report the acquisition of the Stock Options in the \"A\" column of Column 5."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Fully vested on grant date."}],"balance_after":35120,"derivative":{"exercise_price":3.33,"expiration_date":"2030-03-17","underlying":"Common Stock","underlying_shares":35120},"source":{"system":"sec-edgar","filing":"0001209191-20-044379","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1269341/000120919120044379/doc4a.xml","form_type":"4/A","original_submission_date":"2020-03-18"}},{"id":3072397,"issuer":{"id":89585,"kind":"organization","name":"Oncternal Therapeutics, Inc.","symbol":"ONCT"},"owners":[{"id":19061,"kind":"person","name":"VINCENT RICHARD G","position":1,"cik":"0001269341","reported_name":"VINCENT RICHARD G","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option","published_at":"2020-08-01T01:05:49.000Z","date":"2019-09-12","kind":"grant","acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-fourth (1/4th) of the shares subject to the stock options shall vest on first anniversary of the date of grant, and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments over the three-year period thereafter, subject to the Reporting Persons continued employment or service with the Issuer on each such date."}],"balance_after":75000,"derivative":{"exercise_price":5.76,"expiration_date":"2029-09-12","underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0001209191-20-044376","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1269341/000120919120044376/doc4a.xml","form_type":"4/A","original_submission_date":"2015-09-16"}},{"id":3202170,"issuer":{"id":89585,"kind":"organization","name":"Oncternal Therapeutics, Inc.","symbol":"ONCT"},"owners":[{"id":19061,"kind":"person","name":"VINCENT RICHARD G","position":1,"cik":"0001269341","reported_name":"VINCENT RICHARD G","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option","published_at":"2020-03-18T22:49:45.000Z","date":"2020-03-17","kind":"grant","acquired":false,"shares":35120,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Fully vested on grant date."}],"balance_after":35120,"derivative":{"exercise_price":3.33,"expiration_date":"2030-03-17","underlying":"Common Stock","underlying_shares":35120},"source":{"system":"sec-edgar","filing":"0001209191-20-020092","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1269341/000120919120020092/doc4.xml","form_type":"4"}},{"id":3413767,"issuer":{"id":89585,"kind":"organization","name":"Oncternal Therapeutics, Inc.","symbol":"ONCT"},"owners":[{"id":19061,"kind":"person","name":"VINCENT RICHARD G","position":1,"cik":"0001269341","reported_name":"VINCENT RICHARD G","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option","published_at":"2019-09-16T21:38:37.000Z","date":"2019-09-12","kind":"grant","acquired":false,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-fourth (1/4th) of the shares subject to the stock options shall vest on first anniversary of the date of grant, and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments over the three-year period thereafter, subject to the Reporting Persons continued employment or service with the Issuer on each such date."}],"balance_after":75000,"derivative":{"exercise_price":5.76,"expiration_date":"2029-09-12","underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0001209191-19-049689","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1269341/000120919119049689/doc4.xml","form_type":"4"}},{"id":3493991,"issuer":{"id":89585,"kind":"organization","name":"Oncternal Therapeutics, Inc.","symbol":"ONCT"},"owners":[{"id":19061,"kind":"person","name":"VINCENT RICHARD G","position":1,"cik":"0001269341","reported_name":"VINCENT RICHARD G","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Warrants","published_at":"2019-06-11T22:34:42.000Z","date":"2019-06-07","kind":"grant","acquired":true,"shares":281,"ownership":{"direct":false,"nature":"By family trust."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger dated as of April 30, 2019 (the \"Merger Agreement\"), by and among Oncternal Therapeutics, Inc. (\"Old Oncternal\"), GTx, Inc. (\"GTx\") and certain of their subsidiaries, on June 7, 2019 (the \"Effective Time\"), GTx was merged with and into Old Oncternal, with GTx surviving as the continuing entity. At the Effective Time, each share of Old Oncternal common stock issued and outstanding immediately prior to such time was converted into the right to receive 0.073386 shares of the Issuer's common stock. On the trading day immediately prior to the effective time, the closing price of the Issuer's common stock was $1.20 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The warrants are currently exercisable."}],"balance_after":281,"derivative":{"exercise_price":6.13,"expiration_date":"2022-09-12","underlying":"Common Stock","underlying_shares":281},"source":{"system":"sec-edgar","filing":"0000899243-19-016481","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1269341/000089924319016481/doc4.xml","form_type":"4"}},{"id":3493990,"issuer":{"id":89585,"kind":"organization","name":"Oncternal Therapeutics, Inc.","symbol":"ONCT"},"owners":[{"id":19061,"kind":"person","name":"VINCENT RICHARD G","position":1,"cik":"0001269341","reported_name":"VINCENT RICHARD G","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Options","published_at":"2019-06-11T22:34:42.000Z","date":"2019-06-07","kind":"grant","acquired":true,"shares":73385,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger dated as of April 30, 2019 (the \"Merger Agreement\"), by and among Oncternal Therapeutics, Inc. (\"Old Oncternal\"), GTx, Inc. (\"GTx\") and certain of their subsidiaries, on June 7, 2019 (the \"Effective Time\"), GTx was merged with and into Old Oncternal, with GTx surviving as the continuing entity. At the Effective Time, each share of Old Oncternal common stock issued and outstanding immediately prior to such time was converted into the right to receive 0.073386 shares of the Issuer's common stock. On the trading day immediately prior to the effective time, the closing price of the Issuer's common stock was $1.20 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Twenty-five percent of the shares subject to the option will vest on November 7, 2019. The remainder of the shares subject to the option will vest in thirty-six equal montly installments beginning on December 7, 2019."}],"balance_after":73385,"derivative":{"exercise_price":0.81,"expiration_date":"2028-11-14","underlying":"Common Stock","underlying_shares":73385},"source":{"system":"sec-edgar","filing":"0000899243-19-016481","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1269341/000089924319016481/doc4.xml","form_type":"4"}},{"id":3493989,"issuer":{"id":89585,"kind":"organization","name":"Oncternal Therapeutics, Inc.","symbol":"ONCT"},"owners":[{"id":19061,"kind":"person","name":"VINCENT RICHARD G","position":1,"cik":"0001269341","reported_name":"VINCENT RICHARD G","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2019-06-11T22:34:42.000Z","date":"2019-06-07","kind":"grant","acquired":true,"shares":1834,"ownership":{"direct":false,"nature":"By child."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger dated as of April 30, 2019 (the \"Merger Agreement\"), by and among Oncternal Therapeutics, Inc. (\"Old Oncternal\"), GTx, Inc. (\"GTx\") and certain of their subsidiaries, on June 7, 2019 (the \"Effective Time\"), GTx was merged with and into Old Oncternal, with GTx surviving as the continuing entity. At the Effective Time, each share of Old Oncternal common stock issued and outstanding immediately prior to such time was converted into the right to receive 0.073386 shares of the Issuer's common stock. On the trading day immediately prior to the effective time, the closing price of the Issuer's common stock was $1.20 per share."}],"balance_after":1834,"source":{"system":"sec-edgar","filing":"0000899243-19-016481","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1269341/000089924319016481/doc4.xml","form_type":"4"}},{"id":3493988,"issuer":{"id":89585,"kind":"organization","name":"Oncternal Therapeutics, Inc.","symbol":"ONCT"},"owners":[{"id":19061,"kind":"person","name":"VINCENT RICHARD G","position":1,"cik":"0001269341","reported_name":"VINCENT RICHARD G","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2019-06-11T22:34:42.000Z","date":"2019-06-07","kind":"grant","acquired":true,"shares":4526,"ownership":{"direct":false,"nature":"By family trust."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger dated as of April 30, 2019 (the \"Merger Agreement\"), by and among Oncternal Therapeutics, Inc. (\"Old Oncternal\"), GTx, Inc. (\"GTx\") and certain of their subsidiaries, on June 7, 2019 (the \"Effective Time\"), GTx was merged with and into Old Oncternal, with GTx surviving as the continuing entity. At the Effective Time, each share of Old Oncternal common stock issued and outstanding immediately prior to such time was converted into the right to receive 0.073386 shares of the Issuer's common stock. On the trading day immediately prior to the effective time, the closing price of the Issuer's common stock was $1.20 per share."}],"balance_after":4526,"source":{"system":"sec-edgar","filing":"0000899243-19-016481","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1269341/000089924319016481/doc4.xml","form_type":"4"}},{"id":3493987,"issuer":{"id":89585,"kind":"organization","name":"Oncternal Therapeutics, Inc.","symbol":"ONCT"},"owners":[{"id":19061,"kind":"person","name":"VINCENT RICHARD G","position":1,"cik":"0001269341","reported_name":"VINCENT RICHARD G","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2019-06-11T22:34:42.000Z","date":"2019-06-07","kind":"grant","acquired":true,"shares":42628,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger dated as of April 30, 2019 (the \"Merger Agreement\"), by and among Oncternal Therapeutics, Inc. (\"Old Oncternal\"), GTx, Inc. (\"GTx\") and certain of their subsidiaries, on June 7, 2019 (the \"Effective Time\"), GTx was merged with and into Old Oncternal, with GTx surviving as the continuing entity. At the Effective Time, each share of Old Oncternal common stock issued and outstanding immediately prior to such time was converted into the right to receive 0.073386 shares of the Issuer's common stock. On the trading day immediately prior to the effective time, the closing price of the Issuer's common stock was $1.20 per share."}],"balance_after":40794,"source":{"system":"sec-edgar","filing":"0000899243-19-016481","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1269341/000089924319016481/doc4.xml","form_type":"4"}}]}